Phase I study of vemurafenib in children with recurrent or progressive BRAFV600E mutant brain tumors: Pacific Pediatric Neuro-Oncology Consortium study (PNOC-002)

Authors

Theodore Nicolaides, NYU Langone Health
Karen Gauvain, Washington University School of Medicine in St. Louis
et al

Journal

Oncotarget

Publication Date

2020

Volume

11

Issue

21

First Page

1942

Last Page

1952

Document Type

Open Access Publication

DOI

10.18632/oncotarget.27600.

Rights and Permissions

Nicolaides T, Nazemi KJ, Crawford J, Kilburn L, Minturn J, Gajjar A, Gauvain K, Leary S, Dhall G, Aboian M, Robinson G, Long-Boyle J, Wang H, Molinaro AM, Mueller S, Prados M. Phase I study of vemurafenib in children with recurrent or progressive BRAFV600E mutant brain tumors: Pacific Pediatric Neuro-Oncology Consortium study (PNOC-002). Oncotarget. 2020 May 26;11(21):1942-1952. doi: 10.18632/oncotarget.27600. Copyright: Nicolaides et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Recommended Citation

Nicolaides, Theodore; Gauvain, Karen; and et al, "Phase I study of vemurafenib in children with recurrent or progressive BRAFV600E mutant brain tumors: Pacific Pediatric Neuro-Oncology Consortium study (PNOC-002)." Oncotarget. 11, 21. 1942 - 1952. (2020).
https://digitalcommons.wustl.edu/open_access_pubs/9727